Ongoing circulation of established Omicron sublineages such as XFG, NB.1.8.1, and BA.3.2 without any meeting WHO or ECDC criteria for variant of concern status underpins the 80.5% trader consensus on "No." These lineages show limited additional immune escape or fitness advantages over prior strains, with stable or declining proportions in global sequencing and no linked rise in severe outcomes or hospitalizations as of September 2026. Wastewater and clinical surveillance indicate typical seasonal patterns at lower overall levels than previous years, supported by broad population immunity from prior infections and updated vaccines. While new mutations could emerge, the absence of rapid dominance by any novel lineage in the past year aligns with market pricing for the remaining period through 2026.